Cargando…

CYP1A2 – a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients

BACKGROUND: Endocrine resistance is a major obstacle to optimal treatment effect in breast cancer. Some genetic markers have been proposed to predict response to aromatase inhibitors (AIs) but the data is insufficient. The aim of the study was to find new genetic treatment predictive markers of AIs....

Descripción completa

Detalles Bibliográficos
Autores principales:	Simonsson, Maria, Veerla, Srinivas, Markkula, Andrea, Rose, Carsten, Ingvar, Christian, Jernström, Helena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815192/ https://www.ncbi.nlm.nih.gov/pubmed/27029552 http://dx.doi.org/10.1186/s12885-016-2284-3

Ejemplares similares

Pre- and postoperative alcohol consumption in breast cancer patients: impact on early events
por: Simonsson, Maria, et al.
Publicado: (2014)

IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort
por: Markkula, Andrea, et al.
Publicado: (2014)

Excessive milk production during breast-feeding prior to breast cancer diagnosis is associated with increased risk for early events
por: Gustbée, Emma, et al.
Publicado: (2013)

Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort
por: Persson, Mia, et al.
Publicado: (2016)

Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients
por: Markkula, Andrea, et al.
Publicado: (2014)

Body Mass Index Influences the Prognostic Impact of Combined Nuclear Insulin Receptor and Estrogen Receptor Expression in Primary Breast Cancer
por: Björner, Sofie, et al.
Publicado: (2017)

Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients
por: Gustbée, Emma, et al.
Publicado: (2015)

Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients
por: Tryggvadottir, Helga, et al.
Publicado: (2018)

Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups
por: Björner, Sofie, et al.
Publicado: (2016)

Increasing preoperative body size in breast cancer patients between 2002 and 2016: implications for prognosis
por: Wisse, Agatha, et al.
Publicado: (2018)

CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients
por: Jernström, H, et al.
Publicado: (2009)

Coffee Is Associated With Lower Breast Tumor Insulin-Like Growth Factor Receptor 1 Levels in Normal-Weight Patients and Improved Prognosis Following Tamoxifen or Radiotherapy Treatment
por: Björner, Sofie, et al.
Publicado: (2018)

Genetic variants of CYP19 (aromatase) and breast cancer risk
por: Nedelcheva Kristensen, V, et al.
Publicado: (2000)

Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk
por: Siegelmann-Danieli, N, et al.
Publicado: (1999)

Sweet’s Syndrome Induced by Aromatase Inhibitor in the Treatment of Early Breast Cancer
por: Cardoso, Debora, et al.
Publicado: (2020)

Absence of the common Insulin-like growth factor-1 19-repeat allele is associated with early age at breast cancer diagnosis in multiparous women
por: Bågeman, E, et al.
Publicado: (2007)

Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis
por: Artigalás, Osvaldo, et al.
Publicado: (2015)

Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer
por: Magnani, Luca, et al.
Publicado: (2017)

Update on the use of aromatase inhibitors in early-stage breast cancer
por: Kesisis, Georgios, et al.
Publicado: (2009)

Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors
por: Mao, Jun J, et al.
Publicado: (2011)

Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)

Analysis of the rs10046 Polymorphism of Aromatase (CYP19) in Premenopausal Onset of Human Breast Cancer
por: Zins, Karin, et al.
Publicado: (2014)

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects
por: Henry, N L, et al.
Publicado: (2013)

Pyridine based dual binding site aromatase (CYP19A1) inhibitors
por: Eissa, Ahmed G., et al.
Publicado: (2023)

Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer
por: Daldorff, Stine, et al.
Publicado: (2017)

Aromatase inhibitor strategies in metastatic breast cancer
por: McArthur, Heather L, et al.
Publicado: (2010)

Clinical utilities of aromatase inhibitors in breast cancer
por: Chumsri, Saranya
Publicado: (2015)

From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors
por: Vasconcelos de Matos, Leonor, et al.
Publicado: (2021)

Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.
por: Lønning, P. E.
Publicado: (1998)

Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2013)

Adjuvant Aromatase Inhibitors in Early Breast Cancer May Not Increase the Risk of Falls
por: Choksi, Palak, et al.
Publicado: (2016)

Expression of Estrogen-Related Gene Markers in Breast Cancer Tissue Predicts Aromatase Inhibitor Responsiveness
por: Moy, Irene, et al.
Publicado: (2013)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors
por: Romero, Sally A.D., et al.
Publicado: (2019)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

Aromatase inhibitors in advanced breast cancer: there are efficacy differences
por: Bhatnagar, A S
Publicado: (2005)

Evolution of aromatase inhibitors as an endocrine treatment for breast cancer
por: Miller, WR
Publicado: (2006)

Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer
por: Gonnelli, Stefano, et al.
Publicado: (2008)

Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy
por: Balakrishnan, A, et al.
Publicado: (2011)

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer
por: López-Knowles, Elena, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o54gp0ge5bn8oqdnas4380gsof